FDA Grants Fast Track Designation for Cubist Pharmaceuticals, Inc. (CBST)’s Late-Stage Antibiotic Candidate
5/7/2013 11:12:04 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
LEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that the U.S. Food and Drug Administration (FDA) has granted the Company’s late-stage antibiotic candidate ceftolozane/tazobactam (CXA-201) Fast Track status in the previously granted Qualified Infectious Disease Product (QIDP) indications, Hospital-Acquired Bacterial Pneumonia (HABP)/Ventilator-Associated Bacterial Pneumonia (VABP) and Complicated Urinary Tract Infections (cUTI). The FDA granted Fast Track status for ceftolozane/tazobactam in Complicated Intra-Abdominal Infections (cIAI) in February 2013.
Help employers find you! Check out all the jobs and post your resume.
comments powered by